PMH40 National Estimates and Potential Predictors of Emergency Department (ED) and Inpatient Care Costs for Events Related to Abuse or Misuse of Opioid Analgesics  by Chandwani, H. et al.
PMH35
COST-EFFECTIVENESS OF AGOMELATINE IN TREATMENT OF MAJOR
DEPRESSIVE DISORDERS IN TURKEY
Tatar M1, Dilbaz N2, Oral ET3, Tan M4
1Hacettepe University, Ankara, ANKARA, Turkey, 2Ankara Numune Research & Training
Hospital, Ankara, Turkey, 3Istanbul Ticaret University, Istanbul, ISTANBUL, Turkey, 4Servier Ilac
ve Arastirma A.S., Istanbul, Turkey
OBJECTIVES:Major Depressive Disorder (MDD) is an important and growing health
problem in Turkey. Inclusion of a new drug in the positive list for its treatment
requires the proof of cost effectiveness. The objective of this study was to assess
the cost effectiveness of Agomelatine versus Venlafaxine and Duloxetine in treat-
ment of MDD in Turkey. The study was undertaken from the payer perspective.
METHODS: A discrete event model, already validated by European health author-
ities was used to compare Agomelatine with Venlafaxine and Duloxetine. An indi-
rect comparison was made between Agomelatine and Duloxetine. In order to re-
flect the real clinical practice, themodel defined 3-6months of treatment, however
the maintenance phase, defined as the recommended time to prevent eventual
recurrences, was modeled longer (12 weeks and 24 weeks).The clinical outcome
was measured as life years in remission. All direct costs for the year 2011 were
taken into account. Costs and benefitswere discounted by 3%and robustness of the
results were tested by Monte Carlo simulation. RESULTS: Incremental Cost Effec-
tiveness Ratios(ICER) were calculated and results were displayed as cost per addi-
tional life year in remission. The ICER was calculated as –18,799 TL/year in remis-
sion for Agomelatine versus Venlafaxine and – 27,453 TL/year in remission for
Agomelatine versus Duloxetine. CONCLUSIONS: Agomelatine dominated Venla-
faxine and Duloxetine in treatment of MDD in Turkey. Sensitivity analyses re-
vealed that the results were robust.
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OBJECTIVES: Due to rapid aging, South Korea is expected to be the world’s second
oldest country by 2050. Dementia has emerged as a major health problem among
old people in South Korea, and since 2010 the Korean Ministry of Health and Wel-
fare (MOHW) has implemented “National Program for Screening Dementia (NPSD)”
as one of the welfare services for the aged. This study aimed to evaluate the cost-
effectiveness of early diagnosis and treatment of dementia. METHODS: A Markov
model was developed using a societal perspective and a 10-year time horizon.
Simulations were performed for hypothetical cohorts of those aged 65, 70, 75, 80
years. Data sources for model parameters included the NPSD database for cohort
characteristics; the National Health Insurance claims database and survey for de-
mentia costs; the meta-analysis for the treatment effect; and published data for
other epidemiology data. Cost per quality-adjusted life-year (QALY) gained from
screening compared with no screening was calculated from 10-year costs and ac-
cumulated QALYs for each strategy. RESULTS: Screening strategies showed a cost
per QALY gained ranging from 38 million Korean Won (KRW, equivalent to
US$32,000) to 41 million KRW (US$ 34,000), depending on the ages selected for
screening. These results were most sensitive to estimates of direct health care
costs and the severity of dementia among those screened. CONCLUSIONS: These
analyses suggest that NPSD need to improve the cost-effectiveness of screening by
identifying patients with mild dementia rather than severe dementia. The early
diagnosis and treatment of dementia failed to achieve cost saving. This could be
explained by some reasons that there is no such a dramatic difference among net
costs of dementia by disease stage in SouthKorea compared to other countries, and
that the benefits of current therapies are marginal.
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OBJECTIVES: Bipolar disorder (BPD) is highly prevalent and is associated with a
significant economic burden. Antipsychotic drugs are one of themainstream treat-
ments for BPD. Asenapine is a new antipsychotic approved in Canada for the treat-
ment to be used in monotherapy or co-therapy in BPD-I and schizophrenia.
Asenapine has shown a comparable efficacy profile to olanzapine. However, in
contrast to olanzapine, it is associated with a favourable metabolic profile and
minimal weight gain. The objective of this study was to assess, from a Canadian
perspective, the economic impact of asenapine compared to olanzapine in the
treatment of BPD-I. METHODS: A combined decision tree and Markov model was
constructed to assess the cost-utility of asenapine compared with olanzapine. The
decision tree takes into account the occurrence of extrapyramidal symptoms (EPS),
the probability of switching to a different antipsychotic, and the probability of
gainingweight. The treatment used in case of switchwas aripiprazole. TheMarkov
model comprises the following states: long-term metabolic complications (diabe-
tes, hypertension, CHDs, and stroke), fatal stroke, fatal CHD, and death by suicide
or other causes. Due to limited data, asenapine was compared with olanzapine
only. Analyses were conducted from both a CanadianMinistry of Health (MoH) and
a societal perspective over a five-year time horizonwith yearly cycles. RESULTS: In
the treatment of BPD-I, asenapine is a dominant strategy over olanzapine from
both a MoH and a societal perspective. Results of the probabilistic sensitivity anal-
ysis indicated that asenapine remains a dominant strategy in 99.2% of the simula-
tions, and this result is robust to the many sensitivity analyses performed.
CONCLUSIONS: This economic evaluation demonstrates that asenapine is a cost-
effective strategy compared to olanzapine in the treatment of BPD-I in Canada.
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OBJECTIVES: Asenapine is a new antipsychotic approved in Canada for the treat-
ment of schizophrenia (SCZ) and bipolar disorder I as monotherapy and co-ther-
apy. Asenapine has shown a comparable efficacy profile to atypical antipsychotics.
In contrast, however, tomost atypical antipsychotics, it is associatedwith a favour-
able metabolic profile as well as with a minimal weight gain. The objective was to
assess, from a Canadian perspective, the economic impact of asenapine compared
to olanzapine, quetiapine, ziprazidone, aripiprazole.METHODS: A combined deci-
sion tree andMarkovmodel was constructed to assess the cost-utility of asenapine
compared with other atypical antipsychotics. The decision tree takes into account
the occurrence of extrapyramidal symptoms (EPS), the probability of switching to a
different antipsychotic, and the probability of gaining weight. The Markov model
comprises the following states: long-term metabolic complications (diabetes, hy-
pertension, CHDs, and stroke), fatal stroke, fatal CHD, and death by suicide or other
causes. In the base-case analysis, asenapinewas compared to olanzapine. Asenap-
ine was also compared with atypical antipsychotics commonly used in Canada.
Analyses were conducted from both a Canadian Ministry of Health (MoH) and a
societal perspective over a five-year time horizon with yearly cycles. RESULTS: In
the treatment of SCZ, asenapine is a dominant strategy over olanzapine from both
an MoH and a societal perspective, and this result is robust to the many sensitivity
analyses performed. Compared to quetiapine, asenapine is also a dominant strat-
egy. Furthermore, asenapine has a favourable economic impact compared to zipra-
zidone and aripripazole, as these antipsychotics are not cost effective compared to
asenapine, with an incremental cost-effectiveness ratio of $63,204/QALY and
$1,485,625/QALY from a MoH perspective and $62,432/QALY and $1,485,623/QALY
from a societal perspective, respectively. CONCLUSIONS: This economic evalua-
tion demonstrates that asenapine is a cost-effective strategy compared to olanzap-
ine and to most atypical antipsychotics used in Canada.
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OBJECTIVES: According to the Centers for Disease Control, nearly twenty percent
of the American workforce has some type of mental disorder. Depression is espe-
cially prevalent, and antidepressant use in the United States. is common; today,
one in ten Americans over the age of 12 takes an antidepressant medication. This
study assesses the relationships between antidepressant medication adherence
and short-term disability costs in a large manufacturing company. METHODS: A
retrospective analysis of pharmacy claims was conducted to identify individuals
within a largemanufacturing companywhowere continuously eligible for a three-
year time frame (between 2001 - 2007) and who received a prescription for an
antidepressant during that time. In those cases where an individual’s eligibility
spanned a longer time period, the most recent three-year span was chosen. The
resulting sample included both treatment-naïve and treatment-experienced pa-
tients.Medical, pharmacy, and short-termdisability costswere calculated for a one
year follow-up. Adherence was measured using proportion of days covered (PDC),
where a PDC80 was considered adherent. Multi-variable linear regression was
used to examine the relationships between cost and adherence, controlling for
patient demographics (age, gender, and job type) and Charlson co-morbidity score.
RESULTS: Among the 14,737 individuals in the study, the mean adherence to an-
tidepressants was 49%, and 28% (N4178) of the study population had a PDC80.
The average total medical/pharmacy costs were higher for the adherent patients.
Individuals who were adherent to their antidepressant medications, howwever,
had lower short-term disability costs ($2129/year) than did the non-adherent
($2440/year). CONCLUSIONS: In general, patients who were adherent to their an-
tidepressant regimens had lower short-term disability costs than did the non-
adherent. Employers concerned with the impact of depression on their employee
costs should pay particular attention to this association between antidepressant
adherence and short-term disability.
PMH40
NATIONAL ESTIMATES AND POTENTIAL PREDICTORS OF EMERGENCY
DEPARTMENT (ED) AND INPATIENT CARE COSTS FOR EVENTS RELATED TO
ABUSE OR MISUSE OF OPIOID ANALGESICS
Chandwani H, Strassels S, Rascati KL, Lawson K, Wilson JP
The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: The purpose of this study was to estimate the effect of clinical and
demographic patient characteristics, and insurance status on hospital charges asso-
ciated with opioid abuse or misuse in the United States. METHODS: Data for this
study were derived from the 2006, 2007, and 2008 Healthcare Cost and Utilization
Project’s Nationwide Emergency Departments Sample (HCUP-NEDS). Events and
charges related to opioid abuse, dependence, or poisoning overall and by insurance
status (Medicaid, Medicare, private insurance, or self-pay) were estimated using ICD-
9-CM codes 304.0X, 304.7X, 305.5X, 965.00, 965.02, and 965.09, accounting for the com-
plex sampling of theHCUP-NEDS. Chargeswere adjusted using the 2010Medical Con-
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sumer PriceHospital Services index.RESULTS: Total chargeswere $9.8; $9.6; and $9.5
billion for 2006, 2007, and2008, respectively. Thehighest total chargeswere associated
with events for which Medicaid was the expected primary payer ($3.3 billion), fol-
lowed by Medicare ($2.2 billion) for each year In 2006, charges were $2.0 billion for
self-paid events, and $1.7 billion for privately insured events; this relationship was
reversed in 2007 and 2008. Adjusted mean per-event charges were $19,413; $19,560;
and $17,690 for 2006, 2007, and 2008, respectively. Compared to events covered by
private insurance, adjusted charges for Medicare- andMedicaid-covered events were
statistically significantlyhigher,while self-paid eventshad significantly lower charges
(p 0.001 for all years). Age, number of comorbidities, presence of cardiac or respira-
tory disease, gastrointestinal hemorrhage, and acute pancreatitis were significantly
positively associated with total charges (p  0.001 for all). CONCLUSIONS: The eco-
nomic burden of opioid abuse on the healthcare system is substantial and associated
charges are related to insurance status. Factors associated with charges for events
related to opioid abuse ormisuse were also identified, resulting in better understand-
ing of costs of opioid abuse andmisuse.
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ANTIDEPRESSANT TREATMENT PATTERNS, HEALTH CARE UTILIZATION AND
COST AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
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This study evaluated treatment patterns, health care resource utilization, and cost associated
with the use of escitalopram, duloxetine, venlafaxine and desvenlafaxine for MDD.
OBJECTIVES: To assess total and disease-related healthcare costs among patients
diagnosedwithMDD.METHODS: This retrospective cohort study used administra-
tive claims from a large health plan. Patients aged 18-64 with 1medical claim for
MDD and  1 pharmacy claim for branded formulations of escitalopram, dulox-
etine, venlafaxine or desvenlafaxine were identified between January 1, 2009 and
November 30, 2009. Patients were excluded if they had a claim for bipolar disorder
or were not continuously enrolled during the study period. Proportion of days
covered (PDC), healthcare utilization and cost were assessed using descriptive sta-
tistics. Generalized linear model (GLM) with the log link function and a gamma
distribution were also used to examine the association between healthcare cost
while controlling for demographic and clinical characteristics. RESULTS: A total of
45,913 patients were identified. Almost half initiated on escitalopram (47%), with
the remaining patients on duloxetine, 25%, venlafaxine, 21%, and desvenlafaxine,
7%. MDD-specific health care cost was lowest for desvenlafaxine ($1948) followed
by escitalopram ($2065), duloxetine ($2867), and venlafaxine ($3078). Likewise, total
cost of care was lowest for desvenlafaxine ($11,480), followed by escitalopram
($11,879), venlafaxine ($13,380) and duloxetine ($16,384). Analyses that controlled
for variables including age, gender, region, pre-index total all cause-related health
care costs, PDC and used desvenlafaxine as reference group, indicated a significant
difference in MDD-related cost (duloxetine: cost ratio (CR)1.270, venlafaxine:
CR1.388, p0.0001 for both; escitalopram: CR0.986, p0.3994) and total cost (du-
loxetine: CR1.139, venlafaxine: CR1.051, p0.05 for both; escitalopram:
CR0.946, p0.0017). CONCLUSIONS: In this population, there appears to be an
association between use of desvenlafaxine and lower post-index MDD specific and
total cost of care, compared to duloxetine and venlafaxine. There may be unob-
servable factors that were not accounted for influencing these results.
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OBJECTIVES: To describe the demographics, prescription drug utilization, medica-
tion adherence, and pharmacy costs for Medicare Advantage and Medicare Pre-
scription Drug Plan members initiated on paliperidone palmitate (PALI-PALM), a
long-acting antipsychotic for treating schizophrenia. METHODS: The Humana
pharmacy claims database was used to identify Medicare Advantage andMedicare
Prescription Drug Plan members with a pharmacy claim for PALI-PALM between
September 1, 2009, and December 31, 2010. Six-month preindex and postindex
observation periods were used to assess medication utilization and medication-
related costs for patients starting PALI-PALM.Medication possession ratio (MPR) for
PALI-PALMwas calculated using a fixed denominator of sixmonths.RESULTS: Four
hundred forty-one patients met the inclusion criteria. Mean (SD) age was 46.9
(12.6) years. Three hundred ninety-seven patients (90.0%) had a low-income sub-
sidy (LIS), and 331 (75.1%) were dually eligible for Medicaid. Patients initiated on
PALI-PALM received amean of 1.9 (1.0) unique antipsychotics during the preindex
period. One hundred six patients (24%) who had initiated on PALI-PALM had re-
ceived 3 or more antipsychotics during the preindex period. Antidepressant
(56.9%), anticonvulsant (49.2%), and antiparkinsonism (39.0%) drugs were themost
frequently observed nonantipsychotic mental health medications during the pre-
index period. Compared with the preindex period, use of benzodiazepines and
nonbenzodiazepine anxiolytics decreased during the postindex period (benzodiaz-
epines: 10.0% versus 7.3%; McNemar’s test, p0.034; nonbenzodiazepine anxiolyt-
ics: 12.5% versus 8.4%; McNemar’s test, p0.007). Two hundred forty-one patients
(54.6%) displayed an MPR for PALI-PALM 0.80 during the 6-month postindex pe-
riod. Analysis regarding medication-related costs will be presented in the poster.
CONCLUSIONS: Amajority of Medicare members who had initiated on PALI-PALM
had a LIS and dual eligibility. Use of multiple antipsychotics during the preindex
period was common among members initiated on PALI-PALM. We observed a re-
duction in the use of benzodiazepines and nonbenzodiazepine anxiolytics among
members receiving PALI-PALM.
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RELEASE AMONG CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT/
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OBJECTIVES: Guanfacine is a centrally-acting alpha-2 adrenoceptor agonist avail-
able in immediate (GIR) and extended release (GXR) formulations. GIR is FDA-
approved for hypertension, but is prescribed off-label for ADHD. GXR is US ap-
proved for symptomatic treatment of pediatric ADHD as mono- or adjunctive
therapy. No outcomes study has compared the two formulations. This study de-
scriptively compares treatment patterns, resource utilization, and cost, between
children and adolescents with ADHD initiating treatment with GIR versus GXR.
METHODS: Patients, aged 6-17, with  1 claim for GIR or GXR from November 1,
2009-December 30, 2010 were identified from a large US commercial medical and
pharmacy claims database. Patients had  1 primary diagnosis of ADHD (ICD-9
codes: 314.00, 314.01) during the baseline period, no prior guanfacine use or hyper-
tension diagnosis, and continuous eligibility for 6-months pre- and post-guanfa-
cine initiation. Patient characteristics, resource utilization and costs were descrip-
tively compared using Chi-square and student t-tests. Treatment patterns were
compared using Log-rank test. RESULTS: The GIR and GXR cohorts included 743
and 2,344 patients, respectively. At baseline, patients initiating GIR had signifi-
cantly more adjunctive therapy use (59.1% versus 54.6%, p0.03), higher total
health care costs ($4250 vs. $3384), and utilization ( 1 hospitalization [8.6% vs.
4.6%],  1 emergency room visit [17.2% vs. 14.0%]) than GXR initiators (all p0.05).
After 6-months, GIR patients switched or discontinuedADHD treatmentmore than
GXR (21.3% vs. 12.8%; 73.5% vs. 53.7%, respectively (all p0.01)). Health care utili-
zation remained significantly greater for GIR patients ( 1 hospitalization [5.4% vs.
3.8%]; p0.05;  1 emergency room visit [16.0% vs. 12.5%]; p0.02), while total
health care costs ($4214 vs. $3934, p0.41) were equivalent. CONCLUSIONS: Pre-
liminary findings indicate children and adolescents may have higher rates of dis-
continuation/switching, and resource utilization when treated with GIR than GXR;
costs were not different. Further adjusted analyses are underway comparing out-
comes between the two drugs.
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OBJECTIVES: While utility improvements from depression treatments have been
studied, little research has examined utility improvements from non-pharmaco-
logical treatments in older minorities. The objective of this study was to measure
utility improvements from Beat the Blues (BTB), a non-pharmacological program
for older depressed African Americans inwhich licensed senior center social work-
ers meet with participants at home for up to 10 sessions over 4 months to assess
care needs, make referrals/linkages, provide depression education, instruct in
stress reduction techniques, and use behavioral activation to identify goals and
steps to achieve them. METHODS: Utility (EQ-5D) was measured in a single-blind
parallel group randomized clinical trial comparing BTB to wait list control. Patients
were enrolled between 2009 and 2010, were African American, age  55, had pos-
itive screen for depression (PHQ-95), English speaking, and cognitively intact.
EQ-5D was administered at T1 (baseline), T2 (4 months) and T3 (8 months). Partic-
ipants receiving control at T1 were switched to BTB at T2 and followed to T3;
participants receiving BTB at T1were switched to observation at T2 and followed to
T3 (“post-BTB”). RESULTS: EQ-5D sample sizes for the study groups were T1-T2:
BTB69; control66, and T2-T3: BTB79; post-BTB70. EQ-5D index values for BTB
versus control at T1 were 0.5701 (0.20 SD) versus 0.5705 (0.21 SD) and improved to
0.6638 (0.22 SD) versus 0.6308 (0.20 SD) at T2 (T1-T2 within group improvements
were 0.0937 and 0.0603 for BTB versus control). EQ-5D index in the post-BTB group
held from T2-T3 (slight 0.0093 within group increase). Participants switched to BTB
from control from T2-T3 showed improvement (0.0655 within group increase).
CONCLUSIONS: BTB resulted in meaningful and sustained utility improvement, in
the range of depression treatments previously studied. Findings inform discus-
sions about health gains which can be expected from non-pharmacological treat-
ments in depressed older, underserved African Americans.
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BACKGROUND: Extensive research exists estimating the effect hazardous alcohol
use on morbidity and mortality, but little research quantifies the association be-
tween alcohol consumption andutility scores in patientswith alcohol dependence.
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